Neurofibromatosis
18
4
4
12
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
11.1%
2 terminated out of 18 trials
85.7%
-0.8% vs benchmark
6%
1 trials in Phase 3/4
50%
6 of 12 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 12 completed trials
Clinical Trials (18)
Natural History Study of Patients With Neurofibromatosis Type 2
Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1
Clinical and Demographic Characteristics of Adult p Atients With NEurofibromatosis in RUSsia
Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1
Validating Pain Scales in Children and Young Adults
GROWing Up With Rare GENEtic Syndromes
Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults
A Long-term Study of NPC-12G Gel in Neurofibromatosis Type I
Acceptance and Commitment Therapy for Adolescents and Young Adults With Neurofibromatosis and Chronic Pain
Study of Sutent®/Sunitinib (SU11248) in Subjects With NF-1 Plexiform Neurofibromas
Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas
Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas
Relationship Between Psychosocial Factors, Health Literacy, Quality of Life and Satisfaction With Medical Visits in Adults With NF
Resiliency Training for Patients With Neurofibromatosis Via Videoconferencing With Skype
Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas
Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma
Quality of Friendships in Children With Neurofibromatosis
Clinical Trial of Pirfenidone in Adult Patients With Neurofibromatosis 1